Friday, 2 July 2021

Hypotonia Market Dynamics, Segments and Supply Demand 2020-2027

 Hypotonia is also known as floppy baby syndrome, or weakness of muscles and lack of muscle tone.   There are two main types of hypotonia – Acquired hypotonia in which hypotonia develops after birth as the result of an underlying medical condition, injury or trauma; and congenital hypotonia in which hypotonia is present at birth. Hypotonia is a symptom rather than a condition. Major causes of hypotonia can either be neurological or non-neurological.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4949

Hypotonia is characterized with diminished muscle tone. The infant or child with hypotonic cerebral palsy appears floppy like a rag doll, hence the name. Hypotonic cerebral palsy is the result of an injury or malformation at an earlier brain developmental stage than that which causes spastic or choreoathetoid cerebral palsy. There are various causes of cerebral palsy which includes brain injury or brain malformation that occurs while the brain is developing i.e before, during, or after birth. As a result of the brain damage, during brain development, a child’s muscle control, muscle coordination, muscle tone, reflex, posture and balance can be affected.

Neurological problems present at birth which affect a child’s movement and co-ordination of brain and spinal cord injury including bleeding in the brain.

According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses in the world including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.

The global hypotonia market is expected to grow at a CAGR of ~5.8% during the forecast period 2017-2023. 

Intended Audience

  • Pharmaceutical and Biotechnological Companies
  • Research and Development (R&D) Companies
  • Ambulatory Care Centers
  • Academic Institutes and Universities
  • Market Research and Consulting Service Providers
  • Potential Investors 

Segmentations

The global hypotonia market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of the type, it is segmented into acquired hypotonia and congenital hypotonia.  

On the basis of diagnosis it is segmented into physical examination, blood tests, muscle biopsy, assessment of cerebrospinal fluid, computerized tomography or CT scan or magnetic resonance imaging (MRI) scan, electroencephalogram, electromyography, metabolic panel tests, assessment of thyroid hormone, nerve conduction velocity, genetic testing, and others.

On the basis of treatment, it is segmented into physiotherapy, occupational therapy, speech and language therapy, drugs, and others. Drugs is further segmented into neostigmine, physostigmine, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Regional Analysis

The Americas dominate the global hypotonia market owing to well-developed technology, increasing patient population, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds second position in the global hypotonia market owing to government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies of the region such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.    

Asia Pacific is the fastest growing hypotonia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.

On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Key Players

Some of key the players in the market are LivaNova PLC (U.K), EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), Boston Scientific Corporation (U.S.), Cyberonics, Inc. (U.S.), NeuroMetrix, Inc.(U.S.), ImThera Medical (U.S.), and Inspire Medical Systems, Inc.(U.S.), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hypotonia-market-4949

Wednesday, 30 June 2021

Dental Lasers Market – Insights on Upcoming Trends 2027

  The global Dental Lasers Market size is estimated reach USD 2.3 billion by 2023 with a CAGR of 5.2% during the forecast period (2017-2023).

The term “LASER” stands for ‘Light Amplification by the Stimulated Emission of Radiation’. Lasers emit a thin and concentrated beam of light, producing a thermal output. This thermal output has been used in the dentistry for endodontic treatment, oral surgery, implantology, peri-implantitis, periodontics, and others.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7375

From the past few years, the dental laser market has expanded with a steady CAGR. Factors such as, increasing prevalence of dental diseases, rising dental healthcare expenditure, growing R&D by the major market players, and increasing dental tourism are estimated to drive the market during the forecast period. Dental caries is a common chronic tooth tissue disease and effects ~90% of the world population (once in the lifetime). In the presence of such high prevalence of dental caries, demand of related therapeutics has increased. It is reportable that dental caries can be removed effectively by the application of dental lasers. Fast procedure and minimal invasion are some of the advantages associated with caries removal by dental lasers.

However, factors such as high cost of dental laser, changing reimbursement policies, lack of skilled work-force and awareness in the developing economies restraints the market growth.  A sophisticated laser system is estimated to cost about USD 300, 000 to USD 500,000 or more.

Segmentation

The global dental lasers market is segmented based on product, application, and end users.

The dental lasers market, by product is segmented into soft tissue dental lasers and all tissue dental lasers. The soft tissue dental lasers is sub-segmented into diode lasers systems, CO2 laser systems, and Nd:YAG laser systems. The all tissue dental lasers segment is divided into Er:YAG laser systems, and Er,Cr:YSGG laser systems.

By application, the market is segmented into endodontic treatment, oral surgery, implantology, peri-implantitis, periodontics, and others.

The dental lasers market, by end user is segmented into hospitals & clinics, ambulatory surgical units, academic & research organizations.

Based on region, the global dental lasers market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Sleep Testing Services Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

  Global sleep testing services market size is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5.9 billion in 2017 and is projected to grow at a CAGR of 13.2% over the forecast period. Sleep testing services are a set of medical tests that are used to recognize and diagnose sleeping disorders. They record breathing patterns, oxygen levels in blood, leg & eye movements, brainwaves and heart rate.

The factors such as increasing prevalence of sleep disorders, private insurance service providers and heavy adoption of the services by people are expected to propel the growth of the market. However, the high cost associated with sleep testing services can hamper the market growth over the forecast period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7275

Segmentation

The Global sleep testing services market has been segmented into diagnostic services, treatment monitoring services and end user.

The market, on the basis of diagnostic services, has been segmented into home sleep testing and in-lab sleep testing. In-lab sleep testing is further segmented into electroencephalogram, full polysomnography, CPAP/BiPAP titration, multiple sleep latency test (MSLT) and maintenance of wakefulness test (MWT).

The market, by treatment monitoring services, has been segmented into obstructive sleep apnea, insomnia, restless legs syndrome, circadian rhythm disorders, narcolepsy and rapid eye movement (REM) sleep disorder. The obstructive sleep apnea segment is expected to hold the largest market share owing to large number of people suffering from the disorder. Insomnia is expected to be the fastest growing segment owing to the growing prevalence of the disorder.

The market, by end users, has been segmented into hospitals, sleep centers, home care settings and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The sleep testing services market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European sleep testing services market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The sleep testing services market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The sleep testing services market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary 

Geographically, the Americas is anticipated to dominate the global sleep testing services market owing to rising prevalence of sleep disorders in the region and rising popularity of the services by American people. According to a data published by the American Academy of Sleep Medicine in September 2014, 25 million adults in the US suffer from obstructive sleep apnea. Europe is expected to hold the second largest position in the global sleep testing services market. The market growth in this region is attributed to the rising awareness of sleep testing services. The sleep testing services market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and the Rest of the Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the growing prevalence of sleep disorders. According to a report published by the Public Library of Science (PLOS) in February 2017, 15% people in China suffer from insomnia. The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/sleep-testing-services-market-7275

Global Substance Abuse Treatment Market size and forecast, 2020-2027

  Global substance abuse treatment market size is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 11.6% over the forecast period. 

Substance abuse refers to the harmful use of psychoactive substances, including alcohol and illicit drugs.

Increasing trends of cigarette smoking in teenagers is one of the prominent factors driving the Substance Abuse Treatment market. According to the 2015 study published in the Clinical and Translational Investigation journal, More than 60% of individuals start smoking at the age of 13 and more than 90% individuals start smoking before reaching 20 years. It is also reported that 5.8% of the Mexican population comprises adolescents between 13 and 15 years. Of them, 42.8% tried a cigarette at some point in their life.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7230

Various other factors such as increasing incidence of drug addiction, technological advancement in the diagnostics industry, rising patient awareness about substance abuse treatment and improvement in treatment rates and healthcare infrastructure are also expected to propel the growth of the market.

However, poor treatment compliance in some countries and reluctance of individuals for accessing treatment can hamper the market growth over the forecast period.

Segmentation

The global substance abuse treatment market is segmented based on abuse type, treatment type, end user, and region.

The global market for substance abuse treatment, by abuse type is segmented into alcohol dependence, tobacco/nicotine addiction, and drug abuse. The drug abuse segment is anticipated to hold the largest market share owing to the increasing addiction of opioid.

The market, by treatment type, is segmented into alcohol addiction treatment, tobacco/nicotine addiction treatment, and drug abuse treatment. The alcohol addiction treatment segment is further classified as disulfiram, acamprosate, and naltrexone. The tobacco/nicotine addiction treatment segment is further classified as nicotine replacement treatment, and non-nicotine medication. The nicotine replacement treatment segment includes nicotine patch, nicotine gum, nicotine lozenge, nicotine spray, and nicotine inhaler. The non-nicotine medication segment includes bupropion, and varenicline. The drug abuse treatment segment is further classified as methadone, buprenorphine, and naltrexone.

Based on end user, the market is segmented into outpatient treatment centres, residential treatment centres, and inpatient treatment centres.

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The substance abuse treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European substance abuse treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The substance abuse treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The substance abuse treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Veterinary Laboratory Testing Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

  Global veterinary laboratory testing service market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2200 million in 2017 and is projected to grow at a CAGR of 10.1% over the forecast period.

The veterinary laboratory tests are usually performed to determine the cause of animal’s disorder.

Rising incidence of zoonotic diseases is one of the key factors driving the veterinary laboratory testing market. According to the Maine Center for Disease Control & Prevention, around 75% of emerging infectious diseases affecting humans are diseases of animal origin. The most commonly occurring zoonotic diseases are Rabies, Ebola Virus Disease, Q fever, and others. Various other factors such as rising awareness about animal diseases, technological advancements in veterinary testing, increasing expenditure on pet insurance and favourable funding policies are also expected to propel the growth of the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7326

However, high cost of veterinary testing and complications associated with the tests can hinder the market growth over the forecast period.

Segmentation

The global veterinary laboratory testing market has been segmented into animal type, technology, product, and end user.

The market, on the basis of animal type, has been segmented into companion animal and livestock animal. The companion animal segment is further classified as dogs, cats, horses and others. The livestock animal segment is further classified as cattle, pigs, poultry and others.

The market, by technology, has been segmented into clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others.

The clinical biochemistry segment is further classified as clinical chemistry analysis, glucose monitoring, and blood gas & electrolyte analysis. The clinical chemistry analysis segment includes clinical chemistry reagent clips and cartridges and clinical chemistry analyzers. The glucose monitoring segment includes blood glucose strips, glucose monitors and urine glucose strips. The blood gas & electrolyte analysis segment includes blood gas and electrolyte reagent clips and cartridges and blood gas & electrolyte analyzers.

The immunodiagnostics segment is further classified as ELISA tests, lateral flow assays, allergen-specific immunodiagnostic tests, immunoassay analyzers, and others. The lateral flow assays segment includes lateral flow rapid tests, and lateral flow strip readers.

The hematology segment is further classified as hematology cartridges, and hematology analyzers.

The molecular diagnostics segment is further classified as polymerase chain reaction (PCR) tests, microarrays, and others.

The urinalysis segment is further classified as urinalysis clips & cartridges/panels, urine analyzers, and urine test strips.

The market, by product, has been segmented into consumables and instruments.

The market, by end user, has been segmented into veterinary hospitals & clinics, in-house testing, research institutes, diagnostic laboratories, and others. The veterinary hospitals & clinics segment held the largest segment of the market in 2017. This can be attributed to the increasing incidence of zoonotic diseases. On the other hand, the academic institutes segment is estimated to be the fastest growing segment.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The veterinary laboratory testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European veterinary laboratory testing market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The veterinary laboratory testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The veterinary laboratory testing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Medication Management Market Dynamics, Segments and Supply Demand 2020-2027

  The Global medication management system market is expected to register a CAGR of 13.4% during the forecast period of 2018 to 2023.

Medication management is a strategy which ensures that the patient understands the purpose of the medications and takes it in the correct manner at the correct time. It also focuses on improving the use of medications for the patient’s condition. Interventions may include medication reconciliation, medication therapy management, patient/family education on medications and medication set-up simulations for the patient.

Rising geriatric population is one of the key factors driving the medication management market.  Older adults tend to have significant comorbidities which in result increase the medication use and escalate the risk of poor outcomes. According to a 2018 study published in the Clinical Epidemiology, in high income countries, polypharmacy affects between 40% and 50% of older adults. Polypharmacy increases the risk of adverse drug-related events in older adults because a higher number of drugs are associated with a higher risk of harmful drug–drug interactions.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7187

Various other factors such as rising healthcare IT funds, and need for reducing healthcare costs.

However, high software implementation and service maintenance costs can hamper the market growth over the forecast period.

Segmentation

The Global medication management market is segmented based on systems, services, mode of delivery, end user and region.

The global market for medication management, by systems is segmented into computerized physician order entry systems, clinical decision support systems, administration software, inventory management systems, automated dispensing systems and assurance systems. The administration software is further classified as electronic medication administration records (eMAR) software and bar code medication administration (BCMA) software. The automated dispensing systems segment is further classified as centralized automated dispensing systems and decentralized automated dispensing systems (ADS). The centralized automated dispensing system includes robots/robotic automated dispensing systems and carousels. The decentralized automated dispensing system (ADS) includes pharmacy-based decentralized automated dispensing systems, ward-based decentralized automated dispensing systems and automated unit-dose decentralized automated dispensing systems.

The market by services segment is divided into point-of-care verification services and adverse drug effects (ADE) surveillance services.

The market by mode of delivery segment is divided into web-based solutions, on-premise solutions and cloud-based solutions.

Based on end user, the market is segmented into hospitals, pharmacies and others

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The Medication management Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Medication management Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Medication management Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Medication management Market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas dominated the global market for medication management owing to increasing polypharmacy, presence of major market players and developed economies like US and Canada within the region. In 2017, BD launched its latest advancement in comprehensive medication management, BD HealthSight platform for enterprise medication management. The BD HealthSight platform connects systems and processes to help hospitals to drive a safer, more efficient medication management process.

In 2017, it was estimated that Europe stood second in the global Medication Management market. This can be attributed to the presence of developed economies like UK, Germany, France, and others within the region boost the market growth.

Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, and increasing government’s support for foreign investments drives the regional markets of the Asia Pacific region. According to a report published by the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was estimated to grow at a CAGR of 22.87% and reach USD 280 billion by 2020.

On the other hand, the Middle East and Africa held least share in the global medication management market due to the presence of poor economies and low per capita income, especially within the African region.

Key players

Some of the key players in the global medication management market are Allscripts Healthcare 0Electric Company, Mckesson Corporation, Medical Information Technology, Inc., Omnicell, Inc., Optum Inc., QuadraMed Affinity Corporation, Siemens Ltd and others.

Urinary Tract Infection (UTI) Drugs Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

 Urinary tract infection (UTI) is the infection of the lower or upper urinary tract generally due to escherichia coli although other bacteria and fundi may be causative organisms. Symptoms include pain with  urination, frequent urination and feeling the need to urinate despite having an empty bladder. Risk factors that may cause UTI include female anatomy, sexual intercourse, diabetes, obesityetc. World Health Organization (WHO) estimates that approximately 50 % of women suffer from UTI at some point of time in their lives resulting in more than 1 million hospitalizations per year. WHO estimates the annual cost of UTI infections treatment to be greater than billion. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI. .

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2540 

The Middle East and African urinary tract infection (UTI) drugs market is growing due to factors such as catheter associated UTI, hospital borne infections (nosocomial infections), child birth, old age, obesity, growing health awareness especially about women health etc. However, there remain market constraints such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases etc. Another prominent restrain is the excellent efficacy of present antibiotics specially the quinolones. However the rise of drug resistance has negated this constraint and had opened doors to new drug development as a good strategy for UTI treatment.

Taking all these factors into consideration, the Middle East and Africa UTI drugs market had reached around $ 992.84 million from $ 769 million in 2015 by growing at the CAGR of 4.35%.

Study Objectives Middle East and Africa UTI Drugs Market:

  • To provide detail analysis of the market structure along with forecast for the next 5 years about various segments and sub segments of the Middle East and African UTI Drugs market.
  • To provide insights about factors affecting the market growth.
  • To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
  • To provide past and estimated future revenue of Middle East and Africa UTI drugs market’s segments and sub-segments.
  • To provide country level analysis of the market with respect to the current market size and future growth prospect.
  • To provide country level analysis of the market’s segments which includes by drug class, by clinical indication, by end users and other sub segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments taking place globally.

Intended Audience

  • UTI drugs manufacturers
  • UTI drugs suppliers
  • Private research laboratories
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Government research laboratories
  • Contract manufacturing organizations

Key Players of Middle East and Africa UTI Drugs Market:

Some of the key players in this market are: Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd. and others.

Segments:

Middle East and Africa UTI drugs market has been segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the market is segmented into hospitals and self-administered.

Regional Analysis of Middle East and Africa UTI Drugs Market:

UAE is the largest market of UTI drugs in Middle East and African UTI drugs market closely followed by Egypt. South Africa ranks high in the agendas of many Indian based pharmaceutical firms. The rest of African market is the fastest growing market of UTI drug since there are huge unmet medical needs.

The report about Middle East and Africa UTI Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value & volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mea-uti-drugs-market-2540